Get the Stockscreener App
14.14
0.78%
0.11
After Hours:
13.99
-0.15
-1.06%
Arcus Biosciences Inc stock is traded at $14.14, with a volume of 665.48K.
It is up +0.78% in the last 24 hours and down -8.77% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$14.03
Open:
$14.27
24h Volume:
665.48K
Relative Volume:
0.96
Market Cap:
$1.29B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-4.5761
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+2.32%
1M Performance:
-8.77%
6M Performance:
-0.98%
1Y Performance:
-7.82%
1-Day Range:
$13.99
$14.36
1-Week Range:
$13.81
$14.52
52-Week Range:
$13.51
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
14.14 | 1.29B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences appoints new Chief Medical Officer - Investing.com
Arcus Biosciences appoints new Chief Medical Officer By Investing.com - Investing.com UK
Arcus Biosciences Announces New Chief Medical Officer - TipRanks
Arcus Biosciences Names Amgen Veteran Richard Markus as CMO to Lead Expanding Phase 3 Pipeline - StockTitan
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by Analysts - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Buy” by Analysts - Defense World
Wells Fargo Initiates Coverage of Arcus Biosciences (RCUS) with Overweight Recommendation - MSN
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
How the (RCUS) price action is used to our Advantage - Stock Traders Daily
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025 - Seeking Alpha
Arcus Biosciences stock hits 52-week low at $13.51 By Investing.com - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Sets New 52-Week LowTime to Sell? - MarketBeat
Arcus: Excellent Pipeline And Collaborations, Cash Runway (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS investor three-year losses grow to 60% as the stock sheds US$79m this past week - Simply Wall St
Robert C. Goeltz II Sells 3,594 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock - MarketBeat
Principal Financial Group Inc. Sells 18,777 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Geode Capital Management LLC Has $18.69 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays PLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Barclays PLC - MarketBeat
(RCUS) Trading Report - Stock Traders Daily
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Buy” by Brokerages - Defense World
Arcus Biosciences Grants Stock Options, RSUs to New Employees Under Inducement Plan - StockTitan
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week - Yahoo Finance
Jane Street Group LLC Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
State Street Corp Lowers Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences to Present at J.P. Morgan Healthcare Conference 2025Key Oncology Updates Expected - StockTitan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 26,966 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
BNP Paribas Financial Markets Has $173,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
(RCUS) Trading Advice - Stock Traders Daily
Arcus Biosciences' SWOT analysis: stock outlook amid HIF2alpha and TIGIT progress - Investing.com
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS) - Simply Wall St
Charles Schwab Investment Management Inc. Has $8.67 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - Marketscreener.com
Arcus Biosciences Awards New Employee Equity Grants Under Inducement Plan - StockTitan
Fmr LLC Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Point72 Asset Management L.P. Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
(RCUS) Investment Analysis and Advice - Stock Traders Daily
Arcus Biosciences' chief accounting officer sells $3,079 in stock - Investing.com
Arcus Biosciences' chief accounting officer sells $3,079 in stock By Investing.com - Investing.com Canada
Parkman Healthcare Partners LLC Acquires 610,219 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Grants New Employee Stock Options and RSUs in Latest Inducement Awards - StockTitan
Walleye Capital LLC Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Suvretta Capital Management LLC Trims Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Algert Global LLC Has $1.73 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus up 4% following Merck Welireg kidney cancer data - MSN
When (RCUS) Moves Investors should Listen - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $14.24 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
RCUS (Arcus Biosciences) Cash-to-Debt : 18.78 (As of Sep. 2024) - GuruFocus.com
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking - Simply Wall St
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):